#ThinkSabio Latest News
confirms receipt of an unsolicited indication of interest from Concentra Biosciences, of which Tang Capital is the controlling shareholder, to acquire ACELYRIN for $3/share in cash plus CVR
confirms receipt of an unsolicited indication of interest from Concentra Biosciences, of which Tang Capital is the controlling shareholder, to acquire ACELYRIN for $3/share in cash plus CVR
